Introduction
============

Pneumoconiosis follows the long-term inhalation of productive dust, which is the primary contributor to pulmonary fibrosis of systemic disease. It is also a progressive fibrotic lung disease, which is caused by occupational exposure to mineral dust and fibers ([@b1-etm-0-0-7166]). It is one of the most serious occupational disease hazards in China ([@b2-etm-0-0-7166]). Currently, occupational hazards exist in \>8,000 enterprises in Xinjiang, China; \>1,300,00 individuals may be contact with occupational hazards and there are \>16,000 patients with various occupational diseases. All types of occupational disease hazard factors are increasing with the process of western development and, although there are certain protective measures, there are increasing numbers of patients with silicosis. According to incomplete current statistics, silicosis not only causes serious damage, due to silicon dust exposure, to the health of workers, but also severely reduces the labor force and quality of life, and causes economic loss to the country ([@b3-etm-0-0-7166]). According to statistics, the economic loss caused by occupational diseases each year is over 140 million RMB. Further investigations on diagnosis are required owing to new challenges in silicosis ([@b4-etm-0-0-7166]).

Surface-enhanced laser desorption ionization flight mass spectrometry (SELDI-TOF-MS) technology was used in the present study to detect the difference in serum protein between patients with silicosis fibrosis and normal healthy individuals, which is a novel effective method for the clinical diagnosis of silicosis by identifying markers for silicosis.

Materials and methods
=====================

### Serum sample information

A total of 60 male patients with silicosis were selected and, according to inclusion criteria and exclusion criteria, 20 patients with clinical cases of silicosis diagnosed within one period were screened and determined as the foundation treatment group, designated as group A. Therefore, of the 60 individuals in total recruited for the study in The Fifth Affiliated Hospital of Xinjiang Medical University (Urumqi, China), 20 patients with silicosis were included. In addition, 20 age-matched healthy patients attending check-ups at the physical examination department in the Fifth Affiliated Clinical Medical College of Xinjiang Medical University were selected as a normal healthy group, designated as group C. The mean age of the three groups were 75.7±4.32 years (group A), 76.1±5.62 years (group B) and 74.8±4.31 years (group C). All samples were collected between June 2014 and July 2015. Groups A and B were patients with silicosis, but the treatment options were different. The treatment of patients in Group A (basic treatment) was as follows: Oxygen therapy, coughing, and expectorant, anti-asthmatic and anti-inflammatory therapy. The treatment of patients in Group B was as follows: basic treatment + 2 ml Deworming Vernonia Injection (repellent spotted chrysanthemum injection; Anhui Golden Sun Biochemical Pharmaceutical Co., Ltd., Fuyang, China) in 10 ml of 0.9% physiological saline for nebulization. Venous blood (5 ml) was centrifuged at 900 × g for 10 min at 4°C; the serum was removed and stored in a freezer at −80°C. Fasting morning venous blood samples were obtained from the normal group (group C), the pre-foundation treatment group (A-Q) and the post-foundation treatment group (A-H). There were a total of 60 samples from the three groups, as each group had 20 biological repeats. SELDI-TOF-MS detection analysis was performed on the samples. The foundation treatment for silicosis comprised chemotherapy using poly 2-vinyl pyridine nitroxide ([@b5-etm-0-0-7166]). Patients with silicosis can be rapidly detected by detecting the plasma levels of tumor necrosis factor-α and matrix metalloproteinase 9 ([@b6-etm-0-0-7166]). The changes in the expression levels of numerous proteins following foundation treatment occur in the same patient and correlate with disease status. The inclusion criteria were as follows: History of dust exposure; early symptoms or signs; X-ray examination as the main basis for the diagnosis of silicosis; laboratory tests for the examination of early diagnostic indicators; pulmonary function tests showing pulmonary ventilation disorders. The exclusion criteria comprised patients who did not meet the inclusion criteria, did not attend follow-up or did not sign the informed consent forms.

### Equipment and instrument

The Ciphergen^®^ SELDI-TOF-MS mass spectrometer (protein fingerprint device) was used in the present study (Ciphergen Biosystems, Inc., Fremont, CA, USA). In order to identify the biomarkers, the Protein Chip SELDI system was used, which can rapidly produce a protein molecular weight map from a large number of complex biological samples. Using surface enhanced laser desorption ion technology, it is able to capture, detect and measure the molecular weight of peptides and proteins in complex biological samples ([@b4-etm-0-0-7166]).

### SELDI protein chip

The covalent coupling of selected proteins or other target molecules can be implemented on the surface of a chip. A particular subgroup of complex protein samples can be captured by the chip through simple chemistry or protein interaction.

Following incubation, protein that was not combined with other ingredients from the chip surface was cleared. Only those specifically binding proteins were retained for further analysis. Following the elution step, the organic solution of energy absorption molecules was added. The chip in the SELDI reading machine was analyzed, which involved a type of time of flight mass spectrometry. Once in a gaseous state, charged protein molecules under the effect of a separation voltage show rapid movement, termed 'flight'. The separation voltage for all the molecules in the sample has the same effect, with differences in time of flight according to the different molecular weight. The SELDI reading machine recorded the time of flight, and converted this to a molecular weight.

### Contrast strategy and analysis of the content

A total of three comparative analyses with the following comparisons, respectively, were performed, and data was obtained for further bioinformatics analysis: C, vs. A-Q; C, vs. A-H; and A-Q, vs. A-H. The data analysis process included data preprocessing, differences in peak screening, hierarchical cluster analysis, Principal Component Analysis (PCA), construction of a decision tree model, and protein prediction based on differences between the peak corresponding to proteins.

### Statistical analysis

SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for the quantitative data, with two sets of equal variances, using a Student\'s t-test. Two sets of heterogeneity of variance, with rank and inspection, disordered classification data were analyzed using the χ^2^ test. The Wilcoxon sum rank test was used with a capacity of \<10. The specific steps of the test were as follows: Firstly, data of two samples were mixed and ranked from the smallest to the largest (the smallest data order is 1 and the largest data order is n1 + n2). Secondly, the ranks of data in the smaller capacity sample are add, that is, the rank sum, denoted by Ť. Thirdly, the T value was compared with the critical value at a certain level of significance in the rank sum test table. If T1\<T\<T2, the difference between the two samples is insignificant; T\<T1 or T≥T2 indicates that the two samples are significantly different. The Wilcoxon rank sum test was used in the present study to obtain P-values. The difference in protein peaks was determined by calculating the P-value to determine the significance of differences of each protein peak. The permutation tests were performed with statistical tools in SIMCA 14.0 software (Umetrics AB, Umea, Sweden). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Data preprocessing

Raw data analyses were performed using Ciphergen Protein Chip software correction processing to obtain the peak data. A mass-to-charge ratio \<1,000 of the peak was considered the substrate peak, and the subsequent data was filtered based on the peak.

### Difference in peak filtering

The peak between two groups was compared using the Wilcoxon sum rank test, using the peak P-value to judge whether there were significant differences between the two groups. By selecting different peaks, differences between peaks were compared and the screening results for C, vs. A-Q ([Table I](#tI-etm-0-0-7166){ref-type="table"}), C, vs. A-H ([Table II](#tII-etm-0-0-7166){ref-type="table"}), and A-Q, vs. S A-H ([Table III](#tIII-etm-0-0-7166){ref-type="table"}) were obtained. As shown in [Table I](#tI-etm-0-0-7166){ref-type="table"}, the normal group and pre-foundation treatment group had statistically significant differences between peaks. As shown in [Table II](#tII-etm-0-0-7166){ref-type="table"}, the normal group and post-foundation treatment group had statistically significant differences between peaks. As shown in [Table III](#tIII-etm-0-0-7166){ref-type="table"}, between the pre- and post-foundation treatment group, there were statistically significant differences in peaks.

### Hierarchical clustering analysis

The hierarchical cluster analysis was performed on the differences in peaks, with a clustering diagram showing the association between the samples. Each line represents a peak in the diagram ([Fig. 1](#f1-etm-0-0-7166){ref-type="fig"}), and each column represents a sample. The red and green colors represent sample testing content is higher and lower, respectively. The comparison results for each group are shown in heat maps: C, vs. A-Q ([Fig. 1A](#f1-etm-0-0-7166){ref-type="fig"}), C, vs. A-H ([Fig. 1B](#f1-etm-0-0-7166){ref-type="fig"}), and A-Q, vs. A-H ([Fig. 1C](#f1-etm-0-0-7166){ref-type="fig"}). Shown in [Fig. 1A](#f1-etm-0-0-7166){ref-type="fig"} is the association between the normal group and pre-foundation treatment group of samples, with red indicating sample testing content was higher and green indicating the sample testing content was lower. In [Fig. 1B](#f1-etm-0-0-7166){ref-type="fig"}, the association between the normal group and post-foundation treatment group of samples is shown. In [Fig. 1C](#f1-etm-0-0-7166){ref-type="fig"}, the association between pre- and post-foundation treatment group samples is shown.

### PCA analysis

Using SIMCA software (version 14), the PCA analysis results were obtained. The scoring results for the total and the comparisons in each group are shown. As shown in [Fig. 2A](#f2-etm-0-0-7166){ref-type="fig"}, the normal group and pre-foundation treatment group were distinguished. As shown in [Fig. 2B](#f2-etm-0-0-7166){ref-type="fig"}, the normal group and post-foundation treatment group were distinguished.

### Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) model construction

The C, vs. A-Q group OPLS-DA scoring chart is shown in [Fig. 3A](#f3-etm-0-0-7166){ref-type="fig"}, the displacement test (permutation test) diagram is shown in [Fig. 3B](#f3-etm-0-0-7166){ref-type="fig"}, and the OPLS-DA load diagram is shown in [Fig. 3C](#f3-etm-0-0-7166){ref-type="fig"}. It was shown that there was a significant difference in the protein level between the normal group and pre-foundation treatment group. The C, vs. A-H group OPLS-DA scoring diagram is shown in [Fig. 4A](#f4-etm-0-0-7166){ref-type="fig"}, the displacement test (permutation test) diagram is shown in [Fig. 4B](#f4-etm-0-0-7166){ref-type="fig"}, and the OPLS-DA load diagram is shown in [Fig. 4C](#f4-etm-0-0-7166){ref-type="fig"}. The protein level was significantly different between the normal group and post-foundation treatment group. The A-Q, vs. A-H group OPLS-DA scoring chart is shown in [Fig. 5A](#f5-etm-0-0-7166){ref-type="fig"}, the displacement test (permutation test) diagram is shown in [Fig. 5B](#f5-etm-0-0-7166){ref-type="fig"} and the OPLS-DA load diagram is shown in [Fig. 5C](#f5-etm-0-0-7166){ref-type="fig"}. A-Q and A-H were markedly different ([Fig. 5A](#f5-etm-0-0-7166){ref-type="fig"}). The displacement test of the OPLS-DA model demonstrated that the intercept of Q2 was less than 0.05, therefore the models were robust ([Fig. 5B](#f5-etm-0-0-7166){ref-type="fig"}). Each point represents a protein that was expressed higher in the sample compared with another ([Fig. 5C](#f5-etm-0-0-7166){ref-type="fig"}). Proteins on the left side of the axis were highly expressed in the A-H group and proteins on the right side of the axis were highly expressed in the A-Q group. These results demonstrate that proteins level were markedly different between the normal group and the post-foundation treatment group.

### Differential protein prediction

Using Swiss-Prot (2017--10 release; <https://www.uniprot.org/uniprot/?query=*&fil=organism%3A%22Homo+sapiens+%28Human%29+%5B9606%5D%22+AND+reviewed%3Ayes>) as the standard protein data in the database, self-owned coding texted software was used to compare this with the amino acid molecular weight of protein, and the most similar was found as the result of the prediction of the protein. The self-owned coding texted software performed peak-to-protein mapping using in-house MATLAB (version 7.5; The MathWorks, Inc., Natick, MA, USA) scripts. Briefly, the amino acid sequence for each protein in the human genome was obtained from UniProt Knowledge Base (KB)/Swiss-Prot (2017--10 release) ([@b7-etm-0-0-7166]). Potential amino acid sequence segmentation was identified in Empirical Proteomic Ontology-KB ([@b7-etm-0-0-7166]). Peaks were mapped to the amino acid sequences based on the molecular weight; a 5% deviation in molecular weight was allowed. Eventually, a list of mapped proteins was compiled into an Excel table. The differences in predicted proteins between C, vs. A-Q ([Table IV](#tIV-etm-0-0-7166){ref-type="table"}), C, vs. A-H ([Table V](#tV-etm-0-0-7166){ref-type="table"}), and A-Q, vs. A-H ([Table VI](#tVI-etm-0-0-7166){ref-type="table"}) were determined. From [Table IV](#tIV-etm-0-0-7166){ref-type="table"}, it was possible to estimate the differences in serum protein between the normal group and pre-foundation treatment group of patients with silicosis. From [Table V](#tV-etm-0-0-7166){ref-type="table"}, differences in serum protein were estimated between the normal group and post-foundation treatment group of patients with silicosis. From [Table VI](#tVI-etm-0-0-7166){ref-type="table"}, it was possible to estimate the differences in serum protein between the patients with silicosis pre-foundation treatment and post-foundation treatment, respectively. These results demonstrate that complement c3 frag, amyloid βa4 protein, hepcidin, fibrinogen α-chain frags, plasma protease c1 inhibitor frag and SERPING1 are markers for silicosis.

Discussion
==========

According to previous studies, the pathological changes of silicosis are the main contributor to pulmonary fibrosis ([@b7-etm-0-0-7166]--[@b11-etm-0-0-7166]). The exact pathogenesis of silicosis remains to be fully elucidated, however, substantial evidence shows the involvement of alveolar macrophages, cytokines, Clara cells, oxidative stress, the immune system of the body, and SiO~2~ can lead to the occurrence and development of silicosis and be important in silicosis ([@b12-etm-0-0-7166]--[@b17-etm-0-0-7166]). The proteins that are differentially expressed in the serum of patients with silicosis are associated with silicosis ([@b18-etm-0-0-7166],[@b19-etm-0-0-7166]). There have been no studies reporting on a correlation between protein expression differences and silicosis-associated mortality.

SELDI-TOF-MS, through chemical or biological treatment on the surface of the protein chip, laser desorption ionization mass spectrometry equipment and artificial intelligence data analysis processing software comprised of three parts, is a type of ultramicro, high flux, fully automatic protein screening technology for blood serum, urine, cell extracts or other samples directly added for identification ([@b20-etm-0-0-7166]). The present study used SELDI-TOF-MS to obtain original data and perform detailed analysis; the main analytical steps included the following: Data pre-processing, differences in peak screening, hierarchical cluster analysis, PCA analysis, construction of a decision tree model, and prediction based on differences in peaks corresponding to proteins. The advantages of this method over current diagnostic methods are the accuracy, speed and low cost of the application clinically ([@b21-etm-0-0-7166]).

The small number of patients is a limitation of the present study, and further investigations are required to corroborate the preliminary results. In particular, for patients with similar infectious diseases, it is possible that similar diseases have a similar pattern of proteins, which should be included in future investigations. A study demonstrated that there is no correlation between protein expression differences and silicosis-associated mortality ([@b22-etm-0-0-7166]). From the above results, the group of patients with silicosis pre- and post-foundation treatment and the normal group showed differences in proteins in serum. Therefore, patients with silicosis fibrosis and normal healthy individuals have differences in serum protein expression; in order to further understand these proteins and improve a simple and feasible method for the diagnosis of patients with silicosis fibrosis, further investigations are to be performed for the identification of these differences in proteins. The aim of the present study was to offer occupational doctors a novel and alternative diagnostic test. The novel method, compared with present diagnostic strategies, of the proposed protein chip requires proper equipment, staff training and money. In conclusion, the present study identified complement c3 frag, amyloid βa4 protein, hepcidin, fibrinogen α-chain frags, plasma protease c1 inhibitor frag and SERPING1 are markers for silicosis.
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![(A) C, vs. A-Q clustering results of peak differences; (B) C, vs. S A-H clustering results of peak differences. (C) A-Q, vs. A-H clustering results of peak differences. C, normal group; A-Q, pre-foundation treatment group; A-H, post-foundation treatment group. The red and green represented the level of protein expression. Relative quantitative protein expression results were normalized; the larger the value the darker the red and the smaller the value the darker the green.](etm-17-03-2172-g00){#f1-etm-0-0-7166}

![Comparison of score plots of PCA model obtained from C, A-Q and A-H groups. (A) C, vs. A-Q PCA scoring chart. (B) C, vs. A-H PCA scoring chart. (C) A-Q, vs. A-H PCA scoring chart. PCA, Principal Component Analysis; C, normal group; A-Q, pre-foundation treatment group; A-H, post-foundation treatment group.](etm-17-03-2172-g01){#f2-etm-0-0-7166}

![C, vs. A-Q group OPLS-DA model. (A) C, vs. A-Q group OPLS-DA scoring diagram shows the score plot of the OPLS-DA model obtained from the C and A-Q groups. (B) C, vs. A-Q group permutation test chart. A total of 200 permutations were performed, and the resulting R2 and Q2 values are plotted. Green circle, R2; blue square, Q2. The green line represents the regression line for R2 and the blue line for Q2. (C) C, vs. A-Q group OPLS-DA load diagram of the loading plot of the OPLS-DA model obtained from the C and A-Q groups. OPLS-DA, Orthogonal Projections to Latent Structures Discriminant Analysis; C, normal group; A-Q, pre-foundation treatment group; A-H, post-foundation treatment group.](etm-17-03-2172-g02){#f3-etm-0-0-7166}

![C, vs. A-H group OPLS-DA model. (A) C, vs. A-H group OPLS-DA scoring chart. (B) C, vs. A-H group displacement test chart. (C) C, vs. A-H group OPLS-DA load diagram. OPLS-DA, Orthogonal Projections to Latent Structures Discriminant Analysis; C, normal group; A-Q, pre-foundation treatment group; A-H, post-foundation treatment group.](etm-17-03-2172-g03){#f4-etm-0-0-7166}

![A-Q, vs. A-H group model. (A) A-Q, vs. A-H group OPLS-DA scoring chart. (B) A-Q, vs. A-H group permutation test chart. (C) A-Q, vs. A-H group OPLS-DA load diagram. OPLS-DA, Orthogonal Projections to Latent Structures Discriminant Analysis; C, normal group; A-Q, pre-foundation treatment group; A-H, post-foundation treatment group.](etm-17-03-2172-g04){#f5-etm-0-0-7166}

###### 

C, vs. A-Q group differences in peak filtering.

  SAMP_GRP   P-value          q-value         VIP       C average     A-Q average
  ---------- ---------------- --------------- --------- ------------- -------------
  M1004_63   2.9018×10^−11^   4.38×10^−9^     2.8325    9.337262319   20.59812918
  M1009_81   2.884×10^−6^     1.4043×10^−5^   1.18109   31.51986384   40.84034414
  M1019_45   4.3527×10^−10^   1.5438×10^−8^   2.63561   4.718782081   12.56350599
  M1031_99   6.529×10^−10^    1.6425×10^−8^   3.48656   7.811703062   21.54302217
  M1083_37   4.9091×10^−6^    2.0583×10^−5^   1.12792   0.294565816   2.199163708
  M1098_33   1.3412×10^−7^    1.1292×10^−6^   1.67063   0.38657576    3.615140978
  M1101_43   9.9241×10^−9^    1.07×10^−7^     2.14677   0.927844358   5.631289799
  M1103_90   2.0167×10^−9^    3.3824×10^−8^   1.64852   0.479273296   3.302777091
  M1114_98   4.0713×10^−7^    2.6719×10^−6^   1.5397    0.418107229   3.207923021
  M1123_40   3.028×10^−8^     2.8566×10^−7^   1.64771   0.54015768    3.571119791
  M1127_55   1.3276×10^−8^    1.3359×10^−7^   1.91652   0.784175155   4.616498053
  M1138_12   9.6475×10^−6^    3.6341×10^−5^   1.25759   0.461889022   2.446496536
  M1144_16   2.0167×10^−9^    3.3824×10^−8^   2.7147    1.740541284   9.570840078
  M1146_35   6.529×10^−10^    1.6425×10^−8^   2.77186   2.612216217   10.34906681
  M1150_36   3.9464×10^−9^    5.4153×10^−8^   1.87836   1.903402107   6.508579836
  M1163_78   0.00010426       0.00029951      1.28628   0.268622126   2.446015217
  M1190_81   2.8978×10^−5^    9.678×10^−5^    1.21026   0.31970599    2.341884927
  M1207_98   6.529×10^−10^    1.6425×10^−8^   2.49502   0.550691748   6.396113855
  M1216_31   2.7567×10^−1^°   1.3978×10^−8^   2.92377   2.903470782   11.45476404
  M1230_37   4.9091×10^−6^    2.0583×10^−5^   1.5803    0.390190586   3.294667162
  M1234_44   1.5646×10^−5^    5.4923×10^−5^   1.72882   1.132329262   5.002732013
  M1259_38   4.0713×10^−7^    2.6719×10^−6^   1.72134   0.668984452   3.864822477
  M1324_75   4.1219×10^−6^    1.8269×10^−5^   1.32713   0.326495903   2.353783547
  M1351_32   0.00025797       0.0006279       1.07649   0.222331714   1.765712861
  M1368_84   2.0167×10^−9^    3.3824×10^−8^   2.00209   0.614290076   4.832761142
  M1435_91   2.4028×10^−6^    1.2236×10^−5^   1.64372   0.304051349   3.099785952
  M1454_17   9.9241×10^−9^    1.07×10^−7^     2.09005   0.237729927   4.569096508
  M1475_93   0.00015512       0.0004181       1.1731    0.172207775   2.014840182
  M1505_23   4.5102×10^−5^    0.00014227      1.27917   0.903329951   3.306640883
  M1625_88   1.6891×10^−7^    1.3726×10^−6^   1.48823   0.535477091   3.408169271
  M1700_90   2.1171×10^−7^    1.6498×10^−6^   1.37375   0.23234938    2.32507649
  M1948_00   0.00015512       0.0004181       1.18882   0.126504245   1.85957764
  M2017_02   2.8292×10^−9^    4.2705×10^−8^   2.28118   3.299510237   10.03986804
  M2879_56   0.00022766       0.00057042      1.78224   6.897042594   14.34943243
  M2959_08   7.5712×10^−7^    4.5713×10^−6^   2.03316   0.916531467   5.060081501
  M3224_97   0.00093342       0.00185385      1.06247   2.49928245    1.090001717
  M3246_10   2.4028×10^−6^    1.2236×10^−5^   1.87892   0.396642163   4.2861341
  M3322_38   0.04595423       0.04441369      1.54968   7.748435198   4.898142987
  M3825_21   0.00074741       0.00154007      1.08572   2.514007357   0.827869797
  M3900_31   0.00022766       0.00057042      1.24374   2.663706342   0.890604754
  M4421_61   5.2082×10^−5^    0.00016044      1.69686   4.732555028   1.951991338
  M4478_27   3.2864×10^−7^    2.3028×10^−6^   1.54532   2.864591283   0.276282046
  M4715_56   3.8989×10^−5^    0.00012563      1.51004   3.657925544   1.239881596

C, normal group; A-Q, pre-foundation treatment group.

###### 

C, vs. A-H group differences in peak filtering.

  SAMP_GRP   P-value       q-value        VIP       C average     A-H average
  ---------- ------------- -------------- --------- ------------- -------------
  M1004_63   1.06×10^−7^   8.18 ×10^−6^   2.75206   9.337262319   18.36057094
  M1009_81   6.91×10^−5^   0.000491       1.4842    31.51986384   40.48819307
  M1019_45   3.45×10^−6^   6.65×10^−5^    1.97222   4.718782081   9.320910566
  M1031_99   6.53×10^−8^   8.18×10^−6^    3.3601    7.811703062   18.49940089
  M1083_37   0.00033       0.001496       1.01317   0.294565816   1.699066783
  M1098_33   0.000595      0.002364       1.56859   0.38657576    2.544233659
  M1101_43   6×10^−5^      0.000455       2.06365   0.927844358   4.239463466
  M1103_90   1.14×10^−5^   0.000135       1.32065   0.479273296   2.349881329
  M1114_98   6×10^−5^      0.000455       1.58215   0.418107229   2.796677459
  M1123_40   0.010314      0.020685       1.14424   0.54015768    2.276438971
  M1127_55   0.001767      0.005778       1.68324   0.784175155   3.442394353
  M1138_12   0.010314      0.020685       1.29039   0.461889022   2.551331219
  M1144_16   9.1×10^−5^    0.000562       2.53058   1.740541284   6.707315793
  M1146_35   0.000258      0.001265       2.35356   2.612216217   7.147118481
  M1150_36   0.000228      0.001156       1.31248   1.903402107   4.223835486
  M1190_81   0.006145      0.015189       1.18846   0.31970599    1.670230569
  M1207_98   6.91×10^−6^   9.69×10^−5^    1.95582   0.550691748   3.644110346
  M1216_31   1.65×10^−6^   4.25×10^−5^    2.35906   2.903470782   8.011714226
  M1225_21   0.008712      0.018838       1.15032   0.055092064   1.468164449
  M1230_37   9.1×10^−5^    0.000562       1.47151   0.390190586   2.300611105
  M1234_44   0.000136      0.000774       1.93723   1.132329262   5.024199001
  M1351_32   0.014297      0.025343       1.11582   0.222331714   1.538636715
  M1368_84   3.36×10^−5^   0.000317       1.76946   0.614290076   3.075023606
  M1454_17   6.91×10^−5^   0.000491       1.6592    0.237729927   2.389504296
  M1625_88   2.88×10^−6^   6.04×10^−5^    1.7615    0.535477091   4.070970461
  M2017_02   0.001291      0.004424       1.25703   3.299510237   6.380801455
  M2879_56   0.002643      0.008118       1.43552   6.897042594   11.9477084
  M2959_08   0.001435      0.004811       1.52917   0.916531467   2.90088487
  M3224_97   0.035011      0.049694       1.06234   2.49928245    1.509255098
  M3246_10   1.13×10^−6^   3.47×10^−5^    1.83767   0.396642163   3.275699253
  M3322_38   0.004681      0.0126         1.88645   7.748435198   4.837010977
  M3825_21   0.011207      0.021603       1.16951   2.514007357   1.159904936
  M3900_31   0.011207      0.021603       1.09896   2.663706342   1.345515395
  M4412_23   0.012166      0.022765       1.03269   2.483203325   1.25835564
  M4421_61   0.003211      0.00949        1.89073   4.732555028   2.263517789
  M4715_56   9.65×10^−6^   0.000122       1.86603   3.657925544   0.858452439
  M4770_22   0.009484      0.019762       1.05903   1.036151502   0.130670044
  M4797_31   0.022719      0.03575        1.37116   4.054278147   1.971892733
  M4825_09   0.014297      0.025343       1.30691   3.330875754   2.065185447
  M4832_49   0.000372      0.00164        1.29409   2.046751735   0.412735635
  M5254_17   0.000201      0.001052       1.5746    1.256545457   4.629496349
  M5341_27   2.64×10^−7^   1.36×10^−5^    4.89611   9.675443865   26.47358094
  M5775_96   0.037519      0.052238       1.1959    2.1058316     0.742538154

C, normal group; A-H, post-foundation treatment group.

###### 

A-Q, vs. A-H group differences in peak filtering.

  SAMP_GRP   P-value    q-value    VIP       A-Q average   A-H average
  ---------- ---------- ---------- --------- ------------- -------------
  M1004_63   0.039989   0.415819   1.16467   20.59813      18.36057
  M1019_45   0.002325   0.220852   2.23625   12.56351      9.320911
  M1123_40   0.044054   0.427081   1.27539   3.57112       2.276439
  M1146_35   0.036234   0.403855   2.52543   10.34907      7.147118
  M1150_36   0.000708   0.220852   1.73778   6.50858       4.223835
  M1207_98   0.013617   0.299041   2.71017   6.396114      3.64411
  M1216_31   0.00639    0.247157   2.00268   11.45476      8.011714
  M1245_23   0.036234   0.403855   2.37039   −0.30271      0.870859
  M1259_38   0.048441   0.437643   1.91349   3.864822      2.087152
  M1324_75   0.021484   0.333673   1.45305   2.353784      1.244105
  M1368_84   0.044054   0.427081   2.00074   4.832761      3.075024
  M1435_91   0.013617   0.299041   1.76205   3.099786      1.304288
  M1475_93   0.048441   0.437643   1.73211   2.01484       0.937137
  M1505_23   0.026642   0.363733   1.35806   3.306641      2.081841
  M1661_24   0.019234   0.317797   2.17012   1.212314      0.238766
  M1694_85   0.004221   0.220852   1.66347   1.245148      0.288131
  M1700_90   0.019234   0.317797   2.19981   2.325076      1.021293
  M2001_69   0.013617   0.299041   1.81131   2.097512      0.993857
  M2017_02   0.002712   0.220852   2.50106   10.03987      6.380801
  M4144_81   0.003654   0.220852   1.30244   −0.13272      0.656736
  M4478_27   0.003654   0.220852   2.15012   0.276282      2.172395
  M4861_39   0.048441   0.437643   1.32359   0.092989      0.802765
  M5642_48   0.007296   0.254484   1.30207   0.955681      0.245088
  M7564_68   0.012079   0.291543   1.54656   0.551073      1.201719

A-Q, pre-foundation treatment group; A-H, post-foundation treatment group.

###### 

C, vs. A-Q group differences protein prediction results.

  SAMP_GRP   P-value        q-value       VIP        ID         MZ_SELDI   Predicted protein                                 Theoretical MZ   Gene name
  ---------- -------------- ------------- ---------- ---------- ---------- ------------------------------------------------- ---------------- -----------
  M1948_00   0.000155115    0.000418099   1.18882    M1948_00   1,948      Complement c3 frag                                1,865.12         C3
  M2017_02   2.83×10^−9^    4.27×10^−8^   2.28E+00   M2017_02   2,017.02   Amyloid βa4 protein                               1,953.10         APP
  M2879_56   0.000227661    0.000570423   1.78224    M2879_56   2,879.56   Hepcidin                                          2,797.41         HAMP
  M3224_97   0.000933418    0.001853851   1.06247    M3224_97   3,224.97   Fibrinogen α-chain frag                           3,262.47         FGA
  M3246_10   2.40×10^−6^    1.22×10^−5^   1.88E+00   M3246_10   3,246.1    Fibrinogen α-chain frag                           3,262.47         FGA
  M3322_38   0.04595423     0.044413687   1.54968    M3322_38   3,322.38   Fibrinogen α-chain frag                           3,262.47         FGA
  M3825_21   0.000747408    0.001540074   1.08572    M3825_21   3,825.21   Neurosecretory protein vgf frag                   3,688.03         VGF
  M3900_31   0.000227661    0.000570423   1.24374    M3900_31   3,900.31   Amyloid βa4 protein                               4,074.54         APP
  M4421_61   5.2×10^−5^     0.000160437   1.69686    M4421_61   4,421.61   α-1-antichymotrypsin, α-1-antichymotrypsin frag   4,343.65         SERPINA3
  M4478_27   3.29×10^−7^    2.30×10^−6^   1.55E+00   M4478_27   4,478.27   α-1-antichymotrypsin, α-1-antichymotrypsin frag   4,343.65         SERPINA3
  M4715_56   3.90×10^−5^    0.000125632   1.51004    M4715_56   4,715.56   Neurosecretory protein vgf frag                   4,823.50         VGF
  M4797_31   0.005617767    0.008299276   1.0441     M4797_31   4,797.31   Neurosecretory protein vgf frag                   4,823.50         VGF
  M5895_90   0.003210931    0.005373126   1.36332    M5895_90   5,895.9    Fibrinogen a-chain frag                           5,904.22         FGA
  M5908_34   5.83×10^−6^    2.32×10^−5^   3.48E+00   M5908_34   5,908.34   Fibrinogen achain frag                            5,904.22         FGA
  M6114_30   0.007330817    0.010059399   1.62262    M6114_30   6,114.3    Apolipoprotein c-i                                6,432.35         APOC1
  M6435_51   5.83×10^−6^    2.32×10^−5^   4.57E+00   M6435_51   6,435.51   Apolipoprotein c-i                                6,630.58         APOC1
  M6599_07   4.91×10^−6^    2.06×10^−5^   1.55E+00   M6599_07   6,599.07   Transthyretin                                     6,880.00         TTR
  M6633_61   0.000835766    0.001682037   4.08017    M6633_61   6,633.61   Transthyretin                                     6,880.00         TTR
  M6814_07   5.21 ×10^−5^   0.000160437   1.25676    M6814_07   6,814.07   Transthyretin                                     6,880.00         TTR
  M6842_25   4.91×10^−6^    2.06×10^−5^   3.20E+00   M6842_25   6,842.25   Transthyretin                                     6,880.00         TTR
  M6854_85   3.29×10^−7^    2.30×10^−6^   2.41E+00   M6854_85   6,854.85   Transthyretin                                     6,880.00         TTR
  M7152_30   0.000530525    0.001161127   1.07687    M7152_30   7,152.3    Transthyretin                                     6,880.00         TTR
  M8600_82   0.018093579    0.02061882    1.40868    M8600_82   8,600.82   Apolipoprotein c-iii                              8,764.67         APOC3
  M8696_24   0.006144956    0.008869015   2.30513    M8696_24   8,696.24   Apolipoprotein c-iii                              8,764.67         APOC3
  M8762_75   1.65×10^−6^    9.07×10^−6^   2.50E+00   M8762_75   8,762.75   Apolipoprotein c-iii                              8,764.67         APOC3
  M8823_58   0.00011921     0.000335954   3.04231    M8823_58   8,823.58   Apolipoprotein c-iii                              8,764.67         APOC3
  M8868_31   0.000667562    0.001405836   1.71114    M8868_31   8,868.31   Apolipoprotein a-ii                               9,303.65         APOA2
  M8923_78   0.000530525    0.001161127   2.0589     M8923_78   8,923.78   Apolipoprotein a-ii                               9,303.65         APOA2
  M9138_93   0.00011921     0.000335954   1.16089    M9138_93   9,138.93   Apolipoprotein a-ii                               9,303.65         APOA2
  M9414_68   7.37×10^−9^    8.75×10^−8^   2.70E+00   M9414_68   9,414.68   Apolipoprotein a-ii                               9,303.65         APOA2
  M9440_33   1.56×10^−5^    5.49×10^−5^   1.62E+00   M9440_33   9,440.33   Apolipoprotein a-ii                               9,303.65         APOA2
  M9633_47   2.88×10^−6^    1.40×10^−5^   1.10E+00   M9633_47   9,633.47   Apolipoprotein a-ii                               9,303.65         APOA2
  M9708_99   0.000291908    0.000688459   1.01733    M9708_99   9,708.99   Apolipoprotein a-ii                               9,303.65         APOA2
  M13886_7   0.000329848    0.000765972   1.03751    M13886_7   13,886.7   Cystatin-c                                        13,347.14        CST3
  M14042_5   2.40×10^−6^    1.22×10^−5^   1.19E+00   M14042_5   14,042.5   Transthyretin                                     13,761.41        TTR

C, vs. A-Q, P\<0.05 (t-test used for data analysis). C, normal group; A-Q, pre-foundation treatment group.

###### 

C, vs. A-H group differences protein prediction results.

  SAMP_GRP   P-value        q-value       VIP        ID         MZ_SELDI   Predicted protein                                     Theoretical MZ   Gene name
  ---------- -------------- ------------- ---------- ---------- ---------- ----------------------------------------------------- ---------------- -----------
  M2017_02   0.001290971    0.004424107   1.25703    M2017_02   2,017.02   Amyloid βa4 protein                                   1,953.10         APP
  M2879_56   0.002642631    0.008117783   1.43552    M2879_56   2,879.56   Hepcidin                                              2,797.41         HAMP
  M2959_08   0.001434955    0.004810632   1.52917    M2959_08   2,959.08   No protein matched.                                                    
  M3224_97   0.03501066     0.049693616   1.06234    M3224_97   3,224.97   Fibrinogen α-chain frag                               3,262.47         FGA
  M3246_10   1.13×10^−6^    3.47×10^−5^   1.84E+00   M3246_10   3,246.1    Fibrinogen α-chain frag                               3,262.47         FGA
  M3322_38   0.004681199    0.012599765   1.88645    M3322_38   3,322.38   Fibrinogen α-chain frag                               3,262.47         FGA
  M3825_21   0.011206767    0.021602908   1.16951    M3825_21   3,825.21   Neurosecretory protein vgf frag                       3,688.03         VGF
  M3900_31   0.011206767    0.021602908   1.09896    M3900_31   3,900.31   Amyloid βa4 protein                                   4,074.54         APP
  M4412_23   0.012165581    0.022764829   1.03269    M4412_23   4,412.23   α-1-antichymotrypsin, alpha-1-antichymotrypsin frag   4,343.65         SERPINA3
  M4421_61   0.003210931    0.00948974    1.89073    M4421_61   4,421.61   α-1-antichymotrypsin, α-1-antichymotrypsin frag       4,343.65         SERPINA3
  M4715_56   9.65 ×10^−6^   0.00012165    1.86603    M4715_56   4,715.56   Neurosecretory protein vgf frag                       4,823.50         VGF
  M4770_22   0.009483607    0.019762305   1.05903    M4770_22   4,770.22   Neurosecretory protein vgf frag                       4,823.50         VGF
  M4797_31   0.022718728    0.035750307   1.37116    M4797_31   4,797.31   Neurosecretory protein vgf frag                       4,823.50         VGF
  M4825_09   0.014297273    0.02534287    1.30691    M4825_09   4,825.09   Neurosecretory protein vgf frag                       4,823.50         VGF
  M4832_49   0.000372206    0.001639974   1.29409    M4832_49   4,832.49   Neurosecretory protein vgf frag                       4,823.50         VGF
  M5775_96   0.037519175    0.052237795   1.1959     M5775_96   5,775.96   Fibrinogen α-chain frag                               5,904.22         FGA
  M5883_70   0.049090325    0.06313916    1.07377    M5883_70   5,883.7    Fibrinogen α-chain frag                               5,904.22         FGA
  M5895_90   0.04595423     0.060326782   1.2068     M5895_90   5,895.9    Fibrinogen α-chain frag                               5,904.22         FGA
  M5908_34   0.000530525    0.002164918   3.30565    M5908_34   5,908.34   Fibrinogen α-chain frag                               5,904.22         FGA
  M5954_71   0.018093579    0.030305345   1.20553    M5954_71   5,954.71   Fibrinogen α-chain frag                               5,904.22         FGA
  M6114_30   0.012165581    0.022764829   1.64383    M6114_30   6,114.3    Apolipoprotein c-i                                    6,432.35         APOC1
  M6435_51   0.000667562    0.002573673   4.89498    M6435_51   6,435.51   Apolipoprotein c-i                                    6,630.58         APOC1
  M6484_93   0.019536762    0.032051368   1.05576    M6484_93   6,484.93   Apolipoprotein c-i                                    6,630.58         APOC1
  M6599_07   0.001041218    0.003734178   1.48867    M6599_07   6,599.07   Transthyretin                                         6,880.00         TTR
  M6633_61   0.006144956    0.015189373   4.32524    M6633_61   6,633.61   Transthyretin                                         6,880.00         TTR
  M6814_07   0.000104264    0.000618417   1.4876     M6814_07   6,814.07   Transthyretin                                         6,880.00         TTR
  M6842_25   0.000419438    0.001796749   3.26991    M6842_25   6,842.25   Transthyretin                                         6,880.00         TTR
  M6854_85   0.000667562    0.002573673   2.37706    M6854_85   6,854.85   Transthyretin                                         6,880.00         TTR
  M7065_82   0.011206767    0.021602908   1.08096    M7065_82   7,065.82   Transthyretin                                         6,880.00         TTR
  M7652_53   0.006144956    0.015189373   1.08712    M7652_53   7,652.53   Osteopontin frag                                      7,658.19         SPP1
  M8600_82   0.013194383    0.023938228   2.21464    M8600_82   8,600.82   Apolipoprotein c-iii                                  8,764.67         APOC3
  M8622_98   0.005617767    0.014306888   1.24828    M8622_98   8,622.98   Apolipoprotein c-iii                                  8,764.67         APOC3
  M8696_24   0.006715009    0.016087017   2.86633    M8696_24   8,696.24   Apolipoprotein c-iii                                  8,764.67         APOC3
  M8762_75   5.83×10^−6^    8.94×10^−5^   2.75E+00   M8762_75   8,762.75   Apolipoprotein c-iii                                  8,764.67         APOC3
  M8823_58   0.003885006    0.01098804    3.27878    M8823_58   8,823.58   Apolipoprotein c-iii                                  8,764.67         APOC3
  M8868_31   0.008711881    0.018837648   1.78778    M8868_31   8,868.31   Apolipoprotein a-ii                                   9,303.65         APOA2
  M9138_93   0.011206767    0.021602908   1.00803    M9138_93   9,138.93   Apolipoprotein a-ii                                   9,303.65         APOA2
  M9414_68   6.18×10^−7^    2.38×10^−5^   3.03E+00   M9414_68   9,414.68   Apolipoprotein a-ii                                   9,303.65         APOA2
  M9440_33   0.000329848    0.001496086   1.70483    M9440_33   9,440.33   Apolipoprotein a-ii                                   9,303.65         APOA2
  M9633_47   7.94 ×10^−5^   0.000526668   1.14282    M9633_47   9,633.47   Apolipoprotein a-ii                                   9,303.65         APOA2
  M13886_7   0.003533771    0.010223786   1.13858    M13886_7   13,886.7   Cystatin-c                                            13,347.14        CST3
  M14042_5   9.10 ×10^−5^   0.000561632   1.26247    M14042_5   14,042.5   Transthyretin                                         13,761.41        TTR

C, vs. A-H, P\<0.05 (t-test used for data analysis). C, normal group; A-H, post-foundation treatment group.

###### 

A-Q, vs. A-H group differences protein prediction results.

  SAMP_GRP   P-value       q-value       VIP       ID         MZ_SELDI   Predicted protein                                 Theoretical MZ   Gene name
  ---------- ------------- ------------- --------- ---------- ---------- ------------------------------------------------- ---------------- -----------
  M2001_69   0.013616562   0.299041303   1.81131   M2001_69   2001.69    Amyloid βa4 protein                               1,953.10         APP
  M2017_02   0.00271225    0.220851981   2.50106   M2017_02   2017.02    Amyloid βa4 protein                               1,953.10         APP
  M4144_81   0.00365448    0.220851981   1.30244   M4144_81   4144.81    Plasma protease c1 inhibitor frag                 4,152.87         SERPING1
  M4478_27   0.00365448    0.220851981   2.15012   M4478_27   4478.27    α-1-antichymotrypsin, α-1-antichymotrypsin frag   4,343.65         SERPINA3
  M4861_39   0.048440933   0.437642642   1.32359   M4861_39   4861.39    Neurosecretory protein vgf frag                   4,823.50         VGF
  M5642_48   0.007295609   0.254483755   1.30207   M5642_48   5642.48    Fibrinogen α-chain frag                           5,904.22         FGA
  M7564_68   0.012079239   0.29154291    1.54656   M7564_68   7564.68    Osteopontin frag                                  7,658.19         SPP1

A-Q, vs. A-H, P\<0.05 (t-test used for data analysis). A-Q, pre-foundation treatment group; A-H, post-foundation treatment group.
